Literature DB >> 23103560

Atorvastatin decreases Toll-like receptor 4 expression and downstream signaling in human monocytic leukemia cells.

Shuan Suo Yang1, Ruogu Li, Xinkai Qu, Weiyi Fang, Zhe Quan.   

Abstract

PURPOSE: We aim to evaluate the effects of atorvastatin on the expression of Toll-like receptor (TLR4) protein and mRNA, and to explore their effects on TLR4-dependent downstream signaling in human monocytic leukemia (THP-1) cells.
METHODS: TLR4 protein and mRNA expression, levels of NF-κB protein, and expression of TNF-α, IL-6, and IL-1β in lipopolysaccharide-induced THP-1 cells after incubation with different concentrations of atorvastatin (0.1, 1, 10, 20μM) were quantified via flow-cytometry, quantitative RT-PCR, western blotting, and ELSIA kits.
RESULTS: Atorvastatin incubation resulted in significant decreases in the levels of TLR4 protein and mRNA, NF-κB expression, and levels of TNF-α, IL-6, and IL-1β in LPS-induced THP-1 cells (P<0.01). However, compared with the untreated control, the expression of these were significantly increased (P<0.01).
CONCLUSIONS: Atorvastatin could inhibit the TLR4 expression and TLR4-dependent downstream signaling in THP-1 cells. These observations imply that the interactions with innate immunity may serve as one of the pleiotropic mechanisms of atorvastatin.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103560     DOI: 10.1016/j.cellimm.2012.09.008

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients.

Authors:  Shao Liang; Ma Aiqun; Li Jiwu; Zhang Ping
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

Review 2.  Statins for neuroprotection in spontaneous intracerebral hemorrhage.

Authors:  Ching-Jen Chen; Dale Ding; Natasha Ironside; Thomas J Buell; Lori J Elder; Amy Warren; Amy P Adams; Sarah J Ratcliffe; Robert F James; Neeraj S Naval; Bradford B Worrall; Karen C Johnston; Andrew M Southerland
Journal:  Neurology       Date:  2019-11-11       Impact factor: 9.910

Review 3.  Molecular targets of statins and their potential side effects: Not all the glitter is gold.

Authors:  Kush K Patel; Viren S Sehgal; Khosrow Kashfi
Journal:  Eur J Pharmacol       Date:  2022-03-20       Impact factor: 4.432

4.  Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease.

Authors:  John D Bowman; Salim Surani; Michael A Horseman
Journal:  Curr Cardiol Rev       Date:  2017

5.  Investigating the mechanisms of Modified Xiaoyaosan (tiaogan-liqi prescription) in suppressing the progression of atherosclerosis, by means of integrative pharmacology and experimental validation.

Authors:  Mingtai Chen; Yong Luo; Ling Men; Bo Lin; Haidan Lin; Ying Li; Guofu Zhong; Xiaoling Zhong; Wenjun Fu; Hua Zhou; Guangdong Tong; Qiang Liu; Jienan Luan
Journal:  Aging (Albany NY)       Date:  2021-04-04       Impact factor: 5.682

Review 6.  Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia.

Authors:  Øystein Bruserud; Håkon Reikvam; Annette Katharina Brenner
Journal:  Molecules       Date:  2022-01-23       Impact factor: 4.411

7.  Atorvastatin Inhibits Inflammatory Response, Attenuates Lipid Deposition, and Improves the Stability of Vulnerable Atherosclerotic Plaques by Modulating Autophagy.

Authors:  Shi Peng; Long-Wei Xu; Xin-Yu Che; Qing-Qing Xiao; Jun Pu; Qin Shao; Ben He
Journal:  Front Pharmacol       Date:  2018-05-03       Impact factor: 5.810

8.  Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone.

Authors:  Shiva Ganjali; Vanessa Bianconi; Peter E Penson; Matteo Pirro; Maciej Banach; Gerald F Watts; Amirhossein Sahebkar
Journal:  Metabolism       Date:  2020-09-23       Impact factor: 8.694

Review 9.  Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways.

Authors:  Khadijeh Koushki; Sanaz Keshavarz Shahbaz; Kazem Mashayekhi; Mahvash Sadeghi; Zeinab Deris Zayeri; Mahdieh Yousefi Taba; Maciej Banach; Khalid Al-Rasadi; Thomas P Johnston; Amirhossein Sahebkar
Journal:  Clin Rev Allergy Immunol       Date:  2021-04       Impact factor: 8.667

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.